Bromfenac Versus Dexamethasone After Cataract Surgery — BVD  

Inflammation Eye Clinical Trial

Official title: Bromfenac 0.09% Versus Dexamethasone 0.1% Ophthalmic Solutions to Reduce Inflammation After Cataract Surgery

Status Completed

Clinical Trial Summary

The aim of the study is to compare bromfenac to dexamethasone eye drops to control inflammation after cataract surgery. Inflammation in the anterior chamber of the eye will be measured by a Laser Flare Photometer (LFP).

Clinical Trial Description

The BVD study is a phase IV, single centre, randomized, active-control, parallel design, open-label trial comparing Bromfenac ophthalmic solution 0.1% and Dexamethasone ophthalmic suspension 0.1% in patients older than 60 years after unilateral cataract surgery.

A total of 76 patients (38 for each arm) will be included in this study. Patients will be selected among subjects who underwent cataract surgery the day before the study enrolment. Enrolment will take place at the participating hospital.

Eligible subjects will be sequentially assigned, according to a computer-generated randomization list (1:1), to one of the following treatment groups:

• Experimental Arm: Bromfenac ophthalmic solution 0.1% eye drops, 2 times per day in the study eye for two weeks;

• Standard Arm: Dexamethasone ophthalmic suspension 0.1% eye drops, 4 times per day in the study eye for the first week and 2 times per day in the study eye for the second week.

Each group must start the drops the day after cataract surgery, for two weeks.

The first post-operative clinical evaluation is planned the day after cataract surgery. The following procedures will be performed on the study eye and data will be collected during this first clinical encounter:

• Eye Drops Usage training

• Concomitant medications

• Best-corrected Visual Acuity

• Laser Flare Photometry

• Slit lamp biomicroscopy

• Intracular pressure (IOP) with pneumotonometer,

• Dilated fundus ophthalmoscopy

• Ocular Comfort Grading Assessment

At least six post-operative follow-up visits are planned after 3, 7, 9, 11, 14 days (±1 day) and 30 days (±3 days) from cataract extraction plus possible adjunctive controls if problems/complications will occur. The following procedures will be performed on the study eye and data will be collected during all clinical encounters:

• Compliance with study medication

• Concomitant medications

• Best-corrected Visual Acuity (only day 7, 14, 30)

• Laser Flare Photometry

• Optical Coherence Tomography testing (only day 30)

• Slit lamp biomicroscopy (only day 7, 14 and 30)

• IOP with pneumotonometer (only day 7, 14 and 30)

• Dilated fundus ophthalmoscopy (only day 30)

• Ocular Comfort Grading Assessment (only day 7, 14 and 30)

• Adverse events ;

Related Conditions & MeSH terms

• Capsule Opacification
• Cataract
• Inflammation
• Inflammation Eye

• NCT number: NCT03317847
• Study type: Interventional
• Source: Arcispedale Santa Maria Nuova-IRCCS
• Status: Completed
• Phase: Phase 4
• Start date: October 16, 2017
• Completion date: December 21, 2018